TIDMIMM

RNS Number : 6313N

Immupharma PLC

01 October 2021

RNS | 1 OCTOBER 2021

ImmuPharma PLC

("ImmuPharma", the "Company" or the "Group")

EURONEXT DELISTING

Date: 18 October 2021

ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, provides an update on its delisting from the Euronext Growth Brussels market, where it has a dual listing with AIM. This proposed de-listing from Euronext Growth Brussels was recently confirmed in the Company's 'Corporate Update' announcement on 29 September 2021.

The Company has received confirmation that the Euronext Listing Board has approved its voluntary delisting request from Euronext Growth Brussels.

The timeframe of the de-listing has been agreed with Euronext. It is envisaged that the shares of ImmuPharma (ISIN: GB0033711010) will be removed from trading on Euronext Growth Brussels, as from the 18 October 2021.

Below is a summary of the delisting schedule as disclosed:

 
 DATE         EVENT 
 15 October   Last day of trading of ImmuPharma's shares on 
  2021         Euronext Growth Brussels 
             --------------------------------------------------- 
 18 October   ImmuPharma's shares de-listed from Euronext Growth 
  2021         Brussels 
             --------------------------------------------------- 
 

End

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 
 For further information please contact: 
   ImmuPharma PLC ( www.immupharma.com ) 
    Tim McCarthy, Chief Executive Officer & 
    Chairman                                      + 44 (0) 207 152 4080 
 
   Lisa Baderoon, Head of Investor Relations 
    & Non-Executive Director                      + 44 (0) 7721 413496 
   SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin                                  +44 (0) 203 36 8 3550 
 
    Stanford Capital Partners (Joint Broker) 
    Patrick Claridge                               +44 20 3650 3650 
    John Howes 
    Bob Pountney 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                   +44 (0) 1483 413500 
   4Reliance (Euronext Growth Listing Sponsor)    +32 (0) 2 747 02 60 
    Jean-Charles Snoy 
 
    Degroof Petercam (Liquidity Provider)          +32 (0) 2 287 95 34 
    Erik De Clippel 
 
    Backstage Communication 
    Olivier Duquaine                               +32 (0) 477 504 784 
    Gunther De Backer                              +32 (0) 475 903 909 
 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor(TM) to fund a new international Phase 3 trial for Lupuzor(TM) and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCDKKBBABKDDCN

(END) Dow Jones Newswires

October 01, 2021 01:59 ET (05:59 GMT)

Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Oct 2021 a Nov 2021 Haga Click aquí para más Gráficas Immupharma.
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Nov 2020 a Nov 2021 Haga Click aquí para más Gráficas Immupharma.